In a Phase 2 trial, patients with early Parkinsons disease taking an older GLP-1 diabetes drug called lixisenatide experienced no worsening of motor symptoms over a year, in contrast to patients on placebo who did, according to the study, published Wednesday in the New England Journal of Medicine
It is not product-use guidance, personal-use guidance, or medical advice
The LifeMD Weight Management Program provides a personalized weight loss plan with professional support and, if approved, prescriptions for glucagon-like peptide-1 (GLP-1) medications
Electrolyte correction
These peptides may help with body composition but dont match the clinical results of GLP-1s and dual/triple agonists
Whether from a dietitian, coach, or community, having guidance makes lifestyle changes more sustainable and less overwhelming